{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T19:51:40Z","timestamp":1786564300409,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jdin.2023.09.006","type":"journal-article","created":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T15:36:39Z","timestamp":1695483399000},"page":"192-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Developing a questionnaire for assessing clinician- and patient-reported outcomes in actinic keratosis: Results from an expert panel"],"prefix":"10.1016","volume":"16","author":[{"given":"Brian","family":"Berman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Grada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7448-7809","authenticated-orcid":false,"given":"Neal","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell","family":"Rigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Del Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Kircik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raidah","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Kasujee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jdin.2023.09.006_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/medicina55040092","article-title":"Prevalence, discontinuation rate, and risk factors for severe local site reactions with topical field treatment options for actinic keratosis of the face and scalp","volume":"55","author":"Balcere","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"8","key":"10.1016\/j.jdin.2023.09.006_bib2","doi-asserted-by":"crossref","first-page":"888","DOI":"10.36849\/JDD.6078","article-title":"Advances and considerations in the management of actinic keratosis: an expert consensus panel report","volume":"20","author":"Del Rosso","year":"2021","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"10.1016\/j.jdin.2023.09.006_bib3","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/cncr.24284","article-title":"Actinic keratoses: natural history and risk of malignant transformation in the veterans affairs topical tretinoin chemoprevention trial","volume":"115","author":"Criscione","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jdin.2023.09.006_bib4","series-title":"Patient Perception of Disease and Treatment Burden and New Treatment Preferences in Actinic Keratosis. Paper presented at: ISPOR; May 15-18, 2022; Washington, DC","author":"Kasujee","year":"2022"},{"key":"10.1016\/j.jdin.2023.09.006_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/CCID.S121323","article-title":"Patient satisfaction and reported outcomes on the management of actinic keratosis","volume":"10","author":"Khanna","year":"2017","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2023.09.006_bib6","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1080\/09546634.2021.1917758","article-title":"Patient assessment of 5-fluorouracil and imiquimod for the treatment of actinic keratoses: a retrospective study of real-world effectiveness","volume":"33","author":"Emmerich","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.jdin.2023.09.006_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14833","article-title":"Patient-reported outcomes of topical therapies in actinic keratosis: a systematic review","volume":"34","author":"Grada","year":"2021","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.jdin.2023.09.006_bib8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bjd.12036","article-title":"Assessing the influence of actinic keratosis on patients' quality of life: the AKQoL questionnaire","volume":"168","author":"Esmann","year":"2013","journal-title":"Br J Dermatol"},{"issue":"9 Suppl S2-S12","key":"10.1016\/j.jdin.2023.09.006_bib9","first-page":"S2","article-title":"Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach","volume":"7","author":"Del Rosso","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jdin.2023.09.006_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.25251\/skin.5.2.1","article-title":"Considerations in the management of actinic keratoses: the importance of adherence and persistence to therapy","volume":"5","author":"Marson","year":"2021","journal-title":"SKIN: J Cutan Med"},{"issue":"1","key":"10.1016\/j.jdin.2023.09.006_bib11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.36849\/JDD.6632","article-title":"Use of topical calcipotriol plus 5-fluorouracil in the treatment of actinic keratosis: a systematic review","volume":"21","author":"Mohney","year":"2022","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2023.09.006_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/ijd.12840","article-title":"A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis","volume":"54","author":"Stockfleth","year":"2015","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2023.09.006_bib13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/jdv.15142","volume":"33","author":"Neri","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdin.2023.09.006_bib14","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.2147\/CCID.S374122","article-title":"Tirbanibulin for actinic keratosis: insights into the mechanism of action","volume":"15","author":"Schlesinger","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2023.09.006_bib15","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1056\/NEJMoa2024040","article-title":"Phase 3 trials of tirbanibulin ointment for actinic keratosis","volume":"384","author":"Blauvelt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdin.2023.09.006_bib16","doi-asserted-by":"crossref","unstructured":"Bhatia N, Armstrong A, Schlesinger T, et al. An Expert Panel Questionnaire (EPQ) For Assessing Patient-Reported and Clinician-Reported Outcomes in Actinic Keratosis. Poster presented at the Fall Clinical Dermatology Conference; October 19-23, 2022; Las Vegas, NV.","DOI":"10.25251\/skin.6.supp.89"},{"issue":"5","key":"10.1016\/j.jdin.2023.09.006_bib17","first-page":"E82","article-title":"Trends in office visits for the five most common skin diseases in the United States","volume":"15","author":"Grada","year":"2022","journal-title":"J Clin Aesthet Dermatol"},{"issue":"11","key":"10.1016\/j.jdin.2023.09.006_bib18","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/jamadermatol.2018.3086","article-title":"Use and cost of actinic keratosis destruction in the medicare part B fee-for-service population, 2007 to 2015","volume":"154","author":"Yeung","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2023.09.006_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2310\/6620.2008.08020","article-title":"Baseline quality of life as measured by skindex-16+5 in patients presenting to a referral center for patch testing","volume":"20","author":"Zug","year":"2009","journal-title":"Dermatitis"},{"key":"10.1016\/j.jdin.2023.09.006_bib20","series-title":"Patient-Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis in Real-World Settings: Proak Study Protocol. Paper presented at: Winter Clinical Dermatology Conference; January 14-19, 2022; Kauai, HI","author":"Berman","year":"2022"},{"issue":"3","key":"10.1016\/j.jdin.2023.09.006_bib21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.25251\/skin.7.3.3","article-title":"Clinician- and patient-reported outcomes with tirbanibulin 1% treatment for actinic keratosis in routine clinical practice across the U.S. (PROAK study)","volume":"7","author":"Schlesinger","year":"2023","journal-title":"SKIN: J Cutan Med"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328723001542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328723001542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T03:58:59Z","timestamp":1740887939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328723001542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":21,"alternative-id":["S2666328723001542"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2023.09.006","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing a questionnaire for assessing clinician- and patient-reported outcomes in actinic keratosis: Results from an expert panel","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2023.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}